An αHER2 antibody–neuraminidase conjugate, which selectively targets the removal of sialic acids from glycans on breast cancer cells, bypasses a glycoimmune checkpoint and enhances tumor cell killing by the host immune system.
- Melissa A. Gray
- Michal A. Stanczak
- Carolyn R. Bertozzi